Compounds > 2-nitro-7-methoxynaphtho(2-1b)furan
Page last updated: 2024-12-06

2-nitro-7-methoxynaphtho(2-1b)furan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-nitro-7-methoxynaphtho(2-1b)furan: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53424
CHEMBL ID7645
SCHEMBL ID11229865
MeSH IDM0097502

Synonyms (22)

Synonym
75965-74-1
nsc329223
naphtho[2, 7-methoxy-2-nitro-
nsc-329223
r 7000
7-methoxy-2-nitronaphtho(2,1-b)furan
ccris 4520
r7000 ,
nsc 329223
brn 5749492
naphtho(2,1-b)furan, 7-methoxy-2-nitro-
2-nitro-7-methoxynaphtho(2,1-b)furan
2-nitro-7-methoxynaphtho(2-1b)furan
CHEMBL7645 ,
7-methoxy-2-nitro-naphtho[2,1-b]furan
7-methoxy-2-nitronaphtho[2,1-b]furan
bdbm50304341
7-methoxy-2-nitrobenzo[e][1]benzofuran
2-nitro-7-methoxynaphtho[2,1-b]furan
DTXSID80226862
SCHEMBL11229865
2-nitro-7-methoxynaphtho[2,1-b]furan, bcr(r) certified reference material
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hepatocyte nuclear factor 4-alphaHomo sapiens (human)EC50 (µMol)2.57002.09002.33002.5700AID455458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
positive regulation of transcription by RNA polymerase IIHepatocyte nuclear factor 4-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIHepatocyte nuclear factor 4-alphaHomo sapiens (human)
transcription by RNA polymerase IIHepatocyte nuclear factor 4-alphaHomo sapiens (human)
ornithine metabolic processHepatocyte nuclear factor 4-alphaHomo sapiens (human)
lipid metabolic processHepatocyte nuclear factor 4-alphaHomo sapiens (human)
xenobiotic metabolic processHepatocyte nuclear factor 4-alphaHomo sapiens (human)
sex differentiationHepatocyte nuclear factor 4-alphaHomo sapiens (human)
blood coagulationHepatocyte nuclear factor 4-alphaHomo sapiens (human)
negative regulation of cell population proliferationHepatocyte nuclear factor 4-alphaHomo sapiens (human)
response to glucoseHepatocyte nuclear factor 4-alphaHomo sapiens (human)
regulation of gastrulationHepatocyte nuclear factor 4-alphaHomo sapiens (human)
regulation of lipid metabolic processHepatocyte nuclear factor 4-alphaHomo sapiens (human)
signal transduction involved in regulation of gene expressionHepatocyte nuclear factor 4-alphaHomo sapiens (human)
negative regulation of cell growthHepatocyte nuclear factor 4-alphaHomo sapiens (human)
intracellular receptor signaling pathwayHepatocyte nuclear factor 4-alphaHomo sapiens (human)
glucose homeostasisHepatocyte nuclear factor 4-alphaHomo sapiens (human)
cholesterol homeostasisHepatocyte nuclear factor 4-alphaHomo sapiens (human)
regulation of circadian rhythmHepatocyte nuclear factor 4-alphaHomo sapiens (human)
negative regulation of DNA-templated transcriptionHepatocyte nuclear factor 4-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionHepatocyte nuclear factor 4-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHepatocyte nuclear factor 4-alphaHomo sapiens (human)
rhythmic processHepatocyte nuclear factor 4-alphaHomo sapiens (human)
regulation of insulin secretionHepatocyte nuclear factor 4-alphaHomo sapiens (human)
lipid homeostasisHepatocyte nuclear factor 4-alphaHomo sapiens (human)
phospholipid homeostasisHepatocyte nuclear factor 4-alphaHomo sapiens (human)
triglyceride homeostasisHepatocyte nuclear factor 4-alphaHomo sapiens (human)
anatomical structure developmentHepatocyte nuclear factor 4-alphaHomo sapiens (human)
cell differentiationHepatocyte nuclear factor 4-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHepatocyte nuclear factor 4-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificHepatocyte nuclear factor 4-alphaHomo sapiens (human)
DNA bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
chromatin bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
DNA-binding transcription factor activityHepatocyte nuclear factor 4-alphaHomo sapiens (human)
signaling receptor bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
fatty acid bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
protein bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
zinc ion bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
protein homodimerization activityHepatocyte nuclear factor 4-alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHepatocyte nuclear factor 4-alphaHomo sapiens (human)
nuclear receptor activityHepatocyte nuclear factor 4-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusHepatocyte nuclear factor 4-alphaHomo sapiens (human)
nucleoplasmHepatocyte nuclear factor 4-alphaHomo sapiens (human)
cytoplasmHepatocyte nuclear factor 4-alphaHomo sapiens (human)
chromatinHepatocyte nuclear factor 4-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID455696Cytotoxicity against human HepG2/C3A cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification of small molecule regulators of the nuclear receptor HNF4alpha based on naphthofuran scaffolds.
AID201366Mutagenicity in Salmonella Typhimurium TA100 was determined1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Mechanistic interpretation of the genotoxicity of nitrofurans (antibacterial agents) using quantitative structure-activity relationships and comparative molecular field analysis.
AID201368Mutagenicity in Salmonella Typhimurium TA98 was determined1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Mechanistic interpretation of the genotoxicity of nitrofurans (antibacterial agents) using quantitative structure-activity relationships and comparative molecular field analysis.
AID455697Agonist activity at AF1 deleted human HNF4alpha7 nuclear receptor expressed in human HepG2/C3A cells co-transfected with LexADBD assessed as increase in transcriptional activity after 16 hrs by beta-galactosidase one hybrid assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification of small molecule regulators of the nuclear receptor HNF4alpha based on naphthofuran scaffolds.
AID23231Calculated partition coefficient (clogP)1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Mechanistic interpretation of the genotoxicity of nitrofurans (antibacterial agents) using quantitative structure-activity relationships and comparative molecular field analysis.
AID70453Genotoxicity (SOSIP) on Escherichia coli PQ37 (SOS induction potential data, as a measure of genotoxicity)1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Mechanistic interpretation of the genotoxicity of nitrofurans (antibacterial agents) using quantitative structure-activity relationships and comparative molecular field analysis.
AID455698Agonist activity at human HNF4alpha7 nuclear receptor LBDdetaF expressed in human HepG2/C3A cells co-transfected with LexADBD assessed as increase in transcriptional activity after 16 hrs by beta-galactosidase one hybrid assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification of small molecule regulators of the nuclear receptor HNF4alpha based on naphthofuran scaffolds.
AID455462Agonist activity at human full length HNF4alpha nuclear receptor expressed in human HepG2/C3A cells co-transfected with LexADBD assessed as increase in transcriptional activity at 9.3 uM by beta-galactosidase one hybrid assay relative to control2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification of small molecule regulators of the nuclear receptor HNF4alpha based on naphthofuran scaffolds.
AID455458Agonist activity at human full length HNF4alpha nuclear receptor expressed in human HepG2/C3A cells co-transfected with LexADBD assessed as increase in transcriptional activity after 16 hrs by beta-galactosidase one hybrid assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification of small molecule regulators of the nuclear receptor HNF4alpha based on naphthofuran scaffolds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (54.84)18.7374
1990's10 (32.26)18.2507
2000's4 (12.90)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.65 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nitrates
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.		1.9810monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
3-methylcholanthrene
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.		1.9710ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		1.9710barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		1.9710alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
4-nitroquinoline-1-oxide
4-nitroquinoline N-oxide : A quinoline N-oxide carrying a nitro substituent at position 4.		2.3720C-nitro compound;
quinoline N-oxide		carcinogenic agent
2-naphthol
2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.		1.9710naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
2'-deoxyadenosine triphosphate
2'-deoxyadenosine triphosphate: RN given refers to unlabeled parent cpd		1.98102'-deoxyadenosine 5'-phosphate;
purine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
2-nitrobenzofuran
[no description available]		1.9810
r 6597
2-nitronaphtho(2,1-b)furan: structure given in first source		2.6830
2-nitro-8-methoxynaphtho(2,1-b)furan
[no description available]		3.0750
triazolealanine
triazolealanine: RN given refers to parent cpd. triazolealanine : A non-proteinogenic alpha-amino acid that is alanine in which one of the methyl hydrogens is replaced by a 1,2,4-triazol-3-yl group.		1.9710non-proteinogenic alpha-amino acid;
triazoles
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.3620
nifuroxazide
nifuroxazide: structure		3.1110benzoic acids
nitrofurantoin
Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.		3.1110imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
phosphorus radioisotopes
Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Cell Transformation, Viral
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.		02.3720
Ataxia Telangiectasia Syndrome
[description not available]		02.3720
African Lymphoma
[description not available]		01.9610
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.3720
Ataxia Telangiectasia
An autosomal recessive inherited disorder characterized by choreoathetosis beginning in childhood, progressive CEREBELLAR ATAXIA; TELANGIECTASIS of CONJUNCTIVA and SKIN; DYSARTHRIA; B- and T-cell immunodeficiency, and RADIOSENSITIVITY to IONIZING RADIATION. Affected individuals are prone to recurrent sinobronchopulmonary infections, lymphoreticular neoplasms, and other malignancies. Serum ALPHA-FETOPROTEINS are usually elevated. (Menkes, Textbook of Child Neurology, 5th ed, p688) The gene for this disorder (ATM) encodes a cell cycle checkpoint protein kinase and has been mapped to chromosome 11 (11q22-q23).		02.3720
Burkitt Lymphoma
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.		01.9610
Leukemia L 1210
[description not available]		01.9610
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9810
Experimental Hepatoma
[description not available]		01.9810
Abnormalities, Autosome
[description not available]		02.3820
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		02.3720
Carcinoma, Epidermoid
[description not available]		02.3720
Papilloma, Squamous Cell
[description not available]		01.9610
Cancer of Stomach
[description not available]		02.3720
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.3720
Papilloma
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)		01.9610
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.3720
EHS Tumor
[description not available]		01.9610